SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (365)7/28/1999 8:39:00 AM
From: Herc  Read Replies (1) of 399
 
The reason that I'm attracted to these drug design companies is that most other small drug companies have one or two products in the pipeline that can fail or succeed anywhere in the clinical trial process. So the risk is incredible; 80% drops in a day. I made a little money on CLPA after it fell precipitously. But it's price movement lately has been inexplicable. Drug design companies seem a lot less risky.

Also, despite the admonitions, one of the drug design companies could do as well as SEPR. Not processing to be an expert, I think SEPR just caught on with internet investors. Their revenues are still small.

Further study of the annual report reveal more "significant agreements" with American Home Products and a "number of biotech companies" for milestone payments and royalty payments. And ARQL's board and advisory scientists have some amazing credentials.

Thanks for the feedback. Unfortunately I don't have time to study all their competitors in depth.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News